Tsingtao Brewery's First-Half Net Profit Gains From Recovery in Consumption
By P.R. Venkat
Tsingtao Brewery's first-half net profit rose 20.1%, mainly supported by higher beer sales and cost controls.
Net profit was 3.43 billion yuan ($470.5 million), while revenue was CNY21.59 billion, rising from CNY19.27 billion in the same period a year earlier, Tsingtao said Monday.
A significant portion of the revenue came from mainland China, followed by Hong Kong, it said. The company which is mainly engaged in the production and distribution of beer.
The lifting of Covid-19 curbs in China has seen a boost in consumption for companies like Tsingtao, which had suffered a drop in revenues and profitability due to the pandemic.
In the first half, the company realized cumulative product sales of 5.023 million kiloliters, up 6.5% on year, adding that after deducting non-recurring items, the company's profit was up 24.6% at CNY3.23 billion.
Write to P.R. Venkat at venkat.pr@wsj.com
(END) Dow Jones Newswires
August 27, 2023 20:04 ET (00:04 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track